UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 97 filers reported holding UNIQURE NV in Q2 2018. The put-call ratio across all filers is 0.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $511,000 | +96.5% | 7,128 | +8.3% | 0.00% | +100.0% |
| Q3 2019 | $260,000 | -59.9% | 6,583 | -20.6% | 0.00% | -60.0% |
| Q2 2019 | $648,000 | +21.6% | 8,296 | -7.2% | 0.01% | +25.0% |
| Q1 2019 | $533,000 | +85.1% | 8,939 | -10.3% | 0.00% | +33.3% |
| Q4 2018 | $288,000 | -16.3% | 9,966 | +5.3% | 0.00% | 0.0% |
| Q3 2018 | $344,000 | +21.6% | 9,464 | +26.5% | 0.00% | -25.0% |
| Q2 2018 | $283,000 | +55.5% | 7,480 | -3.2% | 0.00% | +33.3% |
| Q1 2018 | $182,000 | +22.1% | 7,725 | +1.8% | 0.00% | +50.0% |
| Q4 2017 | $149,000 | +106.9% | 7,589 | +0.9% | 0.00% | +100.0% |
| Q3 2017 | $72,000 | +75.6% | 7,520 | +13.9% | 0.00% | 0.0% |
| Q2 2017 | $41,000 | +70.8% | 6,600 | +60.0% | 0.00% | – |
| Q1 2017 | $24,000 | +84.6% | 4,126 | +74.2% | 0.00% | – |
| Q4 2016 | $13,000 | -35.0% | 2,368 | -9.5% | 0.00% | – |
| Q3 2016 | $20,000 | +11.1% | 2,616 | +3.0% | 0.00% | – |
| Q2 2016 | $18,000 | – | 2,541 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |